Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00910351 · ClinicalTrials.gov registry record · Phase 1
Cipro Inhaler for Cystic Fibrosis Children Ages 6-12
A Phase 1 study, sponsored by Bayer.
- Completed
- Registry status
- Phase 1
- Development phase
- 19
- Enrollment target
NCT00910351 is a Phase 1 study that has completed, run by Bayer. The registered enrollment target is 19 participants.
The verdict
NCT00910351, a Phase 1 study, has completed, sponsored by Bayer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 19 participants
- Enrollment target
Study Summary
Ciprofloxacin PulmoSphere Inhalation Powder appears to be an effective and adequate antibiotic treatment for cystic fibrosis patients with P. aeruginosa colonisation. This planned study is the first study on the use of this new Ciprofloxacin PulmoSphere Inhalation Powder in the pediatric population of 6 to 12 years of age.
Interventions
- DRUG Ciprofloxacin (Cipro, BAYQ3939)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2009-07 |
| Est. Completion | 2010-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00910351
The ClinicalTrials.gov registry entry for NCT00910351 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 19 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bayer, which has 591 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Ciprofloxacin (Cipro, BAYQ3939) is the first listed.
NCT00910351 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00910351 about?
NCT00910351 is a clinical study titled "Cipro Inhaler for Cystic Fibrosis Children Ages 6-12". Ciprofloxacin PulmoSphere Inhalation Powder appears to be an effective and adequate antibiotic treatment for cystic fibrosis patients with P. aeruginosa colonisation. This planned study is the first study on the use of this new Ciprofloxacin PulmoSphere Inhalation Powder in the pediatric population ...
What is the current status of trial NCT00910351?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 19 participants. The study started on 2009-07. Estimated completion is 2010-10.
What interventions are being tested in trial NCT00910351?
The interventions under investigation include: Ciprofloxacin (Cipro, BAYQ3939) (DRUG).
Who is sponsoring clinical trial NCT00910351?
This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.